Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT ID: NCT00881556

Last Updated: 2021-08-17

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-20
• Study Completion Date: 2015-09-30

Brief Summary

Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB.

To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.

Detailed Description

Epidermolysis bullosa (EB), is a diverse group of genodermatoses, which is considered a rare and orphan disease and affects approximately 1 in 20,000 people in the United States for a cumulative total of close to 20,000[1-4]. There are three major subtypes of inherited EB, including EB simplex (EBS), junctional EB (JEB), and dystrophic EB[1-4]. RDEB is among the most severe and represents approximately 10% of all forms of EB[1-4]. A rough estimate would then project that there are several thousand patients with RDEB in the U.S. at the current time. Up to 30 different clinical phenotypes and mutations in at least 10 structural genes in different sub-types of EB have been reported[4-8]. In addition to heritable subtypes of EB, there is an acquired autoimmune form in which the patients develop auto-antibodies directed against similar proteins of the inherited dystrophic forms of EB, including EB acquisita (EBA).

We have previously reported our experience with RIC with BFA [48] in pediatric AlloSCT recipients (mean age 9.5 yrs [1.4-21], 11/4 M/F, 10 non-malignant, 5 malignant disease, [6 sibling, 5 UCB, 5 matched unrelated donor]); median time to ANC ≥ 500/mm3 and platelet count ≥20K/mm3 was 22 and 30 days, respectively. Probability of day +180 and 365 donor chimerism was 90% (Figure 7), and OS was 95% (Figure 8). This conditioning regimen therefore results in a high degree of donor chimerism and survival with minimal regimen related mortality.

Conditions

Epidermolysis Bullosa

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

RIC Group

Reduced Intensity Transplant Conditioning (RIC):

Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days

Group Type: EXPERIMENTAL

Palifermin

Intervention Type: DRUG

60 mcg/kg/day for 6 days

Fludarabine

Intervention Type: DRUG

30 mg/m2 IV x 1 for 6 days

Busulfan

Intervention Type: DRUG

4 mg/kg/day IV divided BID for 4 days

Lorazepam

Intervention Type: DRUG

0.02-0.05 mg/kg for 5 days

Alemtuzumab

Intervention Type: DRUG

20 mg/m2 IV for 5 days

Tacrolimus

Intervention Type: DRUG

0.03mg/kg/24 hours as continuous infusion for 4 days

Interventions

Palifermin

60 mcg/kg/day for 6 days

Intervention Type: DRUG

Fludarabine

30 mg/m2 IV x 1 for 6 days

Intervention Type: DRUG

Busulfan

4 mg/kg/day IV divided BID for 4 days

Intervention Type: DRUG

Lorazepam

0.02-0.05 mg/kg for 5 days

Intervention Type: DRUG

Alemtuzumab

20 mg/m2 IV for 5 days

Intervention Type: DRUG

Tacrolimus

0.03mg/kg/24 hours as continuous infusion for 4 days

Intervention Type: DRUG

Other Intervention Names

Kepivance; Fludara; Myleran; Ativan; Lemtrada; Prograf; Protopic; Hecoria

Eligibility Criteria

Inclusion Criteria

• Recessive Dystrophic Epidermolysis Bullosa (RDEB)
• Diagnosis of RDEB using molecular diagnosis and sequencing of mutations
• Skin biopsy to determine status of type VII collagen
• Age ≤21 years
• Patient must have adequate organ function as below:

1. Adequate renal function defined as:

• Serum creatinine less than or equal to 1.5 x normal, or
• Creatinine clearance or radioisotope glomerular filtration rate (GFR) =40 ml/min/m2 or > 60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range

2. Adequate liver function defined as:

• Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase (AST)) or serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase (ALT))< 5.0 x normal

3. Adequate cardiac function defined as:

• Shortening fraction of ≥28% by echocardiogram, or
• Ejection fraction of ≥48% by radionuclide angiogram or echocardiogram

4. Adequate pulmonary function defined as:

• Uncorrected diffusing capacity of the lungs for carbon monoxide (DLCO) ≥35% by pulmonary function test
• For children who are uncooperative, no evidence of dyspnea at rest

Exclusion Criteria

• Karnofsky/Lansky Performance Score <50%
• Pregnant or nursing
• Uncontrolled bacterial, viral or mold infection
• History or presence of skin squamous cell carcinoma

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Angela Christiano, PhD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

The Children's Hospital

Aurora, Colorado, United States

Children's Memorial Hospital

Chicago, Illinois, United States

Morgan Stanley Children's Hospital of NYP

New York, New York, United States

Countries

United States

Other Identifiers

CHNY-08-536

Identifier Type: OTHER

Identifier Source: secondary_id

AAAD5420

Identifier Type: -

Identifier Source: org_study_id